Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ambenonium→

Ambenonium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7648-98-8
Molecular formula
C28H42Cl2N4O2+2
Molecular weight
537.6 g/mol
Drug class
Reversible acetylcholinesterase inhibitorlong-acting quaternary ammonium cholinergic agent
Mechanism of action
Inhibits acetylcholinesterase, increasing acetylcholine concentrations at the neuromuscular junction and improving neuromuscular transmission. Its quaternary ammonium structure limits central nervous system penetration.
Indications / reported uses
  • Historically used for symptomatic treatment of myasthenia gravis; current availability and authorised status are limited and must be verified in the relevant jurisdiction

Sources: NLM MeSH — Ambenonium · PubMed — Ambenonium and myasthenia gravis clinical literature · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ambenonium Environmental Risk Assessment (ERA) (the Ambenonium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.